Topiloric/Uriadec

Company snapshot

Topiloric/Uriadec is a pharma organization headquartered in SOUTH SAN FRANCISCO, CA, JP. Primary therapeutic focus areas include Solid Tumors, Primary Dysmenorrhea, Prostate cancer, chronic liver disease, Prostatic Neoplasms. NovaPharmaNews links 12 clinical program(s), 0 drug profile(s), and 52 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (9), phase 2 (2), phase 3 (1).

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 52 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Topiloric/Uriadec. Not investment advice.

• Peer + 0 momentum

  CytomX Therapeutics

  TA overlap score 21.6

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Topiloric/Uriadec.

1. Jun 8, 2026 Clinical update

   AgnoMed — Phase 3

2. Jun 8, 2026 Clinical update

   SilMAKin — Phase 1

3. Jun 8, 2026 Clinical update

   ORIC-114 Dose 1 + amivantamab — Phase 1

4. Jun 5, 2026 Clinical update

   ORIC-533 — Phase 1

5. May 26, 2026 Clinical update

   Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer. — Phase 1

View all clinical trial activity →

• What is Topiloric/Uriadec?

  Topiloric/Uriadec is a pharma organization headquartered in SOUTH SAN FRANCISCO, CA, JP. Primary therapeutic focus areas include Solid Tumors, Primary Dysmenorrhea, Prostate cancer, chronic liver disease, Prostatic Neoplasms. NovaPharmaNews links 12 clinical program(s), 0 drug pr

• Is Topiloric/Uriadec publicly traded?

  Topiloric/Uriadec appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Topiloric/Uriadec develop or market?

  We link 7 drug profile(s) where Topiloric/Uriadec is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/oric-pharmaceuticals#company-drugs.

• What are the latest developments for Topiloric/Uriadec?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Topiloric/Uriadec focus on?

  Topiloric/Uriadec focuses on Solid Tumors, Primary Dysmenorrhea, Prostate cancer based on our analysis of their pipeline programs and drug development activities.